Jarislowsky Fraser Ltd cut its position in shares of Sanofi (NYSE:SNY) by 8.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 176,169 shares of the company’s stock after selling 15,475 shares during the period. Jarislowsky Fraser Ltd’s holdings in Sanofi were worth $8,440,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Foundation Resource Management Inc. increased its stake in Sanofi by 0.3% in the second quarter. Foundation Resource Management Inc. now owns 374,359 shares of the company’s stock worth $17,936,000 after buying an additional 998 shares during the last quarter. TNB Financial increased its stake in Sanofi by 13.7% in the second quarter. TNB Financial now owns 33,400 shares of the company’s stock worth $1,600,000 after buying an additional 4,020 shares during the last quarter. Clean Yield Group increased its stake in Sanofi by 0.3% in the second quarter. Clean Yield Group now owns 40,107 shares of the company’s stock worth $1,932,000 after buying an additional 115 shares during the last quarter. OLD National Bancorp IN increased its stake in Sanofi by 4.7% in the second quarter. OLD National Bancorp IN now owns 20,569 shares of the company’s stock worth $986,000 after buying an additional 931 shares during the last quarter. Finally, Eqis Capital Management Inc. increased its stake in Sanofi by 12.5% in the second quarter. Eqis Capital Management Inc. now owns 20,172 shares of the company’s stock worth $966,000 after buying an additional 2,245 shares during the last quarter. Institutional investors own 9.84% of the company’s stock.
Shares of Sanofi (SNY) traded down 0.40% during mid-day trading on Wednesday, hitting $47.55. 310,774 shares of the stock were exchanged. The stock has a market cap of $120.09 billion, a PE ratio of 11.52 and a beta of 0.89. Sanofi has a one year low of $36.81 and a one year high of $50.24. The company has a 50-day moving average of $48.47 and a 200 day moving average of $45.36.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.03. The business had revenue of $8.65 billion during the quarter, compared to analyst estimates of $8.40 billion. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. On average, equities analysts predict that Sanofi will post $3.20 earnings per share for the current year.
A number of analysts have commented on the stock. BidaskClub downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Argus raised their price target on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 9th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a report on Friday, June 2nd. Berenberg Bank downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Finally, TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $67.67.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.